VVelarionINTELLIGENCE
Sign inStart free trial
Start free trial

Allakos Executive Compensation (FY23)

ALLK · Executive and director compensation, fiscal 2022 to 2023
Chief executive, fiscal 2023
◇
Robert Alexander
Latest say-on-pay support
=
May 24, 2024
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
See every company’s exec pay — free for 3 days, no cardSee the plan and pricing

The Allakos brief, $500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
Get the executive briefGet the board briefNo account needed.
Data as of November 5, 2026Latest filing (8-K): May 28, 2024
4 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Allakos brief$500Get the executive brief
Velarion Intel, one year, every company
130 figures on this page: 128 cited to the filing that reported them, 2 calculated from figures it prints. See the citations
What changed from fiscal 2022 to fiscal 2023
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Robert Alexander: $7,366,205 → $6,299,426 (14.5% lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is Allakos' chief executive and what were they paid?
Total compensation for Robert Alexander, Chief Executive Officer and Director, came to $6,299,426 in fiscal 2023. Alexander's total moved 14.5% lower from the $7,366,205 reported for fiscal 2022.
What was Allakos' say-on-pay result?
Shareholders recorded 85.5% support for the say-on-pay proposal at the meeting held May 24, 2024 for fiscal 2023.
Which companies are in Allakos' peer group?
The disclosed peer group names Alector, Inc., Allogene Therapeutics, Inc., AnaptysBio, Inc., Annexon, Inc. and Celldex Therapeutics, Inc., among others.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Robert Alexander
Chief Executive Officer and Director
◇—◇—◇—◇◇
Adam Tomasi
President
◇—◇—◇—◇◇
Baird Radford
Chief Financial Officer
◇—◇—◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Robert Alexander
Chief Executive Officer and Director
◇—◇◇◇—◇◇
Adam Tomasi
President
◇—◇◇◇—◇◇
Baird Radford
Chief Financial Officer
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2023
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Adam TomasiOPTION◇——◇—◇◇
Adam TomasiRSU◇——◇——◇
Baird RadfordOPTION◇——◇—◇◇
Baird RadfordRSU◇——◇——◇
Robert AlexanderRSU◇——◇——◇
Robert AlexanderOPTION◇——◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2023 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Robert AlexanderPSU◇◇——
Option◇—◇1/6/2033
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
Adam TomasiPSU◇◇——
Option◇—◇1/6/2033
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
Baird RadfordPSU◇◇——
Option◇—◇1/6/2033
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇4/19/2031
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2023
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
E. Rand Sutherland
◇—◇———◇
Dolca Thomas
◇—◇———◇
Daniel Janney
Board chair
◇—◇———◇
Robert E. Andreatta
◇—◇———◇
Paul Walker
◇—◇———◇
Steven P. James
◇—◇———◇
Neil Graham
◇—◇———◇
Amy L. Ladd
◇—◇———◇
John McKearn
◇—————◇
Robert Alexander served on the board in fiscal 2023 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2023
  • Alector, Inc. ALEC
  • Allogene Therapeutics, Inc. ALLO
  • AnaptysBio, Inc. ANAB
  • Annexon, Inc. ANNX
  • Celldex Therapeutics, Inc. CLDX
  • Cogent Biosciences, Inc. COGT
  • Evelo Biosciences, Inc. symbol not shown
  • Fulcrum Therapeutics, Inc. FULC
  • Gossamar Bio, Inc. symbol not shown
  • Immunovant, Inc. IMVT
  • Kiniksa Pharmaceuticals, Ltd. KNSA
  • Kodiak Sciences Inc. KOD
  • Mersana Therapeutics, Inc. MRSN
  • Omeros Corporation OMER
  • Outlook Therapeutics, Inc. symbol not shown
  • Piant Therapeutics, Inc. symbol not shown
  • PMV Pharmaceuticals, Inc. PMVP
  • Tricida, Inc. symbol not shown

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2023May 24, 2024=◇◇◇
2020May 25, 2021=◇◇◇

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Robert Alexander (Chief Executive Officer and Director), FY2023 total compensation $6,299,426 (base salary $805,460) [exec_comp, SEC accession 0000950170-24-047043, filed 2024-04-23]

See a complete sample report

Answered within 24 hours, every figure cited to its SEC filing. This is a one-off report: no refunds.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Allakos files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Allakos disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Allakos sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Allakos' disclosed peer group is defensible, who names Allakos back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
130 figures on this page: 128 cited to the filing that reported them, 2 calculated from figures it prints.
128 cited to the filing
2 calculated from the filing

Documents cited

  1. 0000950170-24-064883
    Proposal 3: Advisory Vote on Named Executive Officer Compensation The Company’s stockholders approved, on an advisory non-binding basis, the compensation of the Company's named executive officers.
  2. 0000950170-24-047043
    Fiscal Year 2023 Director Compensation · Grants of Plan-Based Awards · Outstanding Equity Awards at Fiscal 2023 Year-End · Summary Compensation Table for Fiscal Year 2023
  3. 0000950170-23-013693
    Summary Compensation Table
  4. 0001564590-21-030016
    Proposal 3: Advisory Vote on Named Executive Officer Compensation The Company’s stockholders did not approve, on an advisory non-binding basis, the compensation of the Company’s named executive officers.
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Allakos executive compensation, FY2022–FY2023.” https://intel.velarion.ai/comp/ALLK (accessed 2026).
Short form: data: Velarion

The Allakos brief, $500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
Get the executive briefGet the board briefNo account needed.
4 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Allakos and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Peers Allakos discloses

The companies named in ALLK's own disclosed peer group.

Alector, Inc.Allogene Therapeutics, Inc.AnaptysBio, Inc.Annexon, Inc.Celldex Therapeutics, Inc.Cogent Biosciences, Inc.Fulcrum Therapeutics, Inc.Immunovant, Inc.Kiniksa Pharmaceuticals, Ltd.Kodiak Sciences Inc.Mersana Therapeutics, Inc.Omeros CorporationPMV Pharmaceuticals, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy